New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 8, 2014
05:34 EDTABBVAbbVie submits MAAs to EMA for investigational HCV therapy
AbbVie submitted marketing authorization applications, or MAAs, to the European Medicines Agency, or EMA, seeking approval for the company's investigational, all-oral, interferon-free regimen for the treatment of adult patients with chronic genotype 1, or GT1, hepatitis C virus, or HCV, infection. The MAAs are supported by data from the largest all-oral, interferon-free clinical program in GT1 patients conducted to date, which consists of six Phase III studies that include more than 2,300 patients in over 25 countries.
News For ABBV From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 30, 2015
07:32 EDTABBVJuno pact leaves Celgene set for growth past Revlimid, says Deutsche Bank
Subscribe for More Information
June 26, 2015
12:02 EDTABBVEMA adopts positive opinion on AbbVie's Humira for acne inversa
Subscribe for More Information
June 24, 2015
06:12 EDTABBVAbbVie announces new TURQUOISE-III study results
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use